Abstract:ABSTRACT Helicobacter pylori is the primary cause of 78% of gastric cancer cases, providing an opportunity to prevent cancer by controlling a single bacterial pathogen within the complex gastric microbiota. We developed highly selective antimicrobial agents against H. pylori by fusing an H. pylori -binding guide peptide (MM1) to broad-spectrum antimicrobial peptides. The common dairy probiotic Lactococcus lactis was then engineered to secrete these guided antimicrobial peptides (gAMPs). When co-cultured in vitro with H. pylori , the gAMP probiotics lost no toxicity compared to unguided AMP probiotics against the target, H. pylori , while losing >90% of their toxicity against two tested off-target bacteria. To test binding to H. pylori , the MM1 guide was fused to green fluorescent protein (GFP), resulting in enhanced binding compared to unguided GFP as measured by flow cytometry. In contrast, MM1-GFP showed no increased binding over GFP against five different off-target bacteria. These highly selective gAMP probiotics were then tested by oral gavage in mice infected with H. pylori . As a therapy, the probiotics outperformed antibiotic treatment, effectively eliminating H. pylori in just 5 days, and also protected mice from challenge infection as a prophylactic. As expected, the gAMP probiotics were as toxic against H. pylori as the unguided AMP probiotics. However, a strong rebound in gastric species diversity was found with both the selective gAMP probiotics and the non-selective AMP probiotics. Eliminating the extreme microbial dysbiosis caused by H. pylori appeared to be the major factor in diversity recovery. IMPORTANCE Alternatives to antibiotics in the control of Helicobacter pylori and the prevention of gastric cancer are needed. The high prevalence of H. pylori in the human population, the induction of microbial dysbiosis by antibiotics, and increasing antibiotic resistance call for a more sustainable approach. By selectively eliminating the pathogen and retaining the commensal community, H. pylori control may be achieved without adverse health outcomes. Antibiotics are typically used as a therapeutic post-infection, but a more targeted, less disruptive approach could be used as a long-term prophylactic against H. pylori or, by extension, against other gastrointestinal pathogens. Furthermore, the modular nature of the guided antimicrobial peptide (gAMP) technology allows for the substitution of different guides for different pathogens and the use of a cocktail of gAMPs to avoid the development of pathogen resistance.

Critical Role of Antimicrobial Peptide Cathelicidin for Controlling Helicobacter Pylori Survival and Infection

Antibacterial Activities of Peptide HF-18 Against Helicobacter pylori and its Virulence Protein CagA

Bactericidal activities of the cationic steroid CSA-13 and the cathelicidin peptide LL-37 against Helicobacter pylori in simulated gastric juice

Cathelicidin, An Antimicrobial Peptide Produced By Macrophages, Promotes Colon Cancer By Activating The Wnt/Beta-Catenin Pathway

Carbohydrate-Dependent and Antimicrobial Peptide Defence Mechanisms Against Helicobacter pylori Infections

Control of Helicobacter pylori with engineered probiotics secreting selective guided antimicrobial peptides

Selective Killing of Helicobacter Pylori with Ph-Responsive Helix-Coil Conformation Transitionable Antimicrobial Polypeptides.

Antibacterial Effects of Bacteriocin PLNC8 against Helicobacter pylori and Its Potential Mechanism of Action

Probiotic Lactobacillus spp. act Against Helicobacter pylori-induced Inflammation

Effective Treatment of Helicobacter pylori Infection Using Supramolecular Antimicrobial Peptide Hydrogels

In vitro anti-Helicobacter pylori activity and antivirulence activity of cetylpyridinium chloride

A Bioresponsive Genetically Encoded Antimicrobial Crystal for the Oral Treatment of Helicobacter Pylori Infection

Cathelicidin-mediated lipopolysaccharide signaling via intracellular TLR4 in colonic epithelial cells evokes CXCL8 production

Abrogation of Cathepsin C by Helicobacter Pylori Impairs Neutrophil Activation to Promote Gastric Infection

Progress in Cathelicidins Antimicrobial Peptides Research

Cordycepin exhibits anti-bacterial and anti-inflammatory effects against gastritis in Helicobacter pylori-infected mice

Vitamin D3 activates the autolysosomal degradation function against Helicobacter pylori through the PDIA3 receptor in gastric epithelial cells

Antimicrobial Peptide CATH-2 Attenuates Avian Pathogenic E. Coli-Induced Inflammatory Response Via NF-κB/NLRP3/MAPK Pathway and Lysosomal Dysfunction in Macrophages

Cutting edge: mast cell antimicrobial activity is mediated by expression of cathelicidin antimicrobial peptide

Cinnamaldehyde: An effective component of Cinnamomum cassia inhibiting Helicobacter pylori

Vitamin D3 Inhibits Helicobacter pylori Infection by Activating the VitD3/VDR-CAMP Pathway in Mice